<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2022</volume><submitter>Ooya T</submitter><pubmed_abstract>(+)-Catechin conjugated with human serum albumin (CT-HSA) was prepared and evaluated as a drug carrier bearing anticancer effects. It was found that 2.4 mol of CT was conjugate to 1 mol HSA. The CT-HSA has an antioxidant capacity of about 3.3 times the amount of CT in the conjugate. Intracellular incorporation of the CT-HSA was analyzed by fluorescence-activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM) measurements using fluorescein isothiocyanate (FITC)-labelled CT-HSA. The results indicated that the FITC-labelled CT-HSA was incorporated into HeLa cells in a concentration-dependent manner. The CT-HSA enhanced the binding of anticancer drugs (5-fluorouracil (5-Fu) and mitomycin C (MMC)) comparing with HSA, and the CT-HSA mixed with 5-Fu or MMC decreased significant</pubmed_abstract><journal>International journal of food science</journal><pagination>1596687</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9569216</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Catechin-Albumin Conjugates: Enhanced Antioxidant Capacity and Anticancer Effects.</pubmed_title><pmcid>PMC9569216</pmcid><pubmed_authors>Haraguchi I</pubmed_authors><pubmed_authors>Ooya T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Catechin-Albumin Conjugates: Enhanced Antioxidant Capacity and Anticancer Effects.</name><description>(+)-Catechin conjugated with human serum albumin (CT-HSA) was prepared and evaluated as a drug carrier bearing anticancer effects. It was found that 2.4 mol of CT was conjugate to 1 mol HSA. The CT-HSA has an antioxidant capacity of about 3.3 times the amount of CT in the conjugate. Intracellular incorporation of the CT-HSA was analyzed by fluorescence-activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM) measurements using fluorescein isothiocyanate (FITC)-labelled CT-HSA. The results indicated that the FITC-labelled CT-HSA was incorporated into HeLa cells in a concentration-dependent manner. The CT-HSA enhanced the binding of anticancer drugs (5-fluorouracil (5-Fu) and mitomycin C (MMC)) comparing with HSA, and the CT-HSA mixed with 5-Fu or MMC decreased significant</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-20T01:50:15.347Z</modification><creation>2025-04-20T01:50:15.347Z</creation></dates><accession>S-EPMC9569216</accession><cross_references><pubmed>36254123</pubmed><doi>10.1155/2022/1596687</doi></cross_references></HashMap>